Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Albacete
Clinical trial register · Spain

Clinical Trials in Albacete, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
PETHEMA Foundation5 Fundación EPIC5 Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company3 Biobizkaia Health Research Institute2 Novartis Pharmaceuticals2
Site location
Barcelona3238 Madrid3046 Valencia1215 Seville1054 Málaga746
All 453 locations
Target enrolment
to

Trials with a site in Albacete

54 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Active, closed
Jesus Villar
Observational
1,241
Barakaldo, Albacete, Barcelona, León, Madrid, Murcia, Valencia, Valladolid
2026-07-13
Recruiting
PETHEMA Foundation
Phase 2
50
Albacete, Alicante, Burgos, Cáceres, Córdoba, Las Palmas, Las Palmas de Gran Canaria, Lugo
2026-06-12
Not yet open
AB Science
Phase 3
600
Albacete, Barcelona, Donostia / San Sebastian, Granada, Madrid, Murcia, Pamplona, Zamora
2026-06
Recruiting
Biobizkaia Health Research Institute
Phase 4
100
Córdoba, Bilbao, Valladolid, Albacete, Barcelona, Madrid, Majadahonda, Oviedo
2026-05-25
Recruiting
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
NCT07242547Limited-stage Small-cell Lung Cancer, Carcinoma, Small Cell Lung, Respiratory Tract Neoplasms, Thoracic Neoplasms
DrugTarlatamab
Fundación GECP
Phase 2
37
Albacete, Alicante, Elche, Barcelona, Manresa, Bilbao, Jerez de la Frontera, Lugo
2026-05-20
Not yet open
Treatment for Ph-negative ALL for Adults up to 65 Years
NCT07443592Acute Lymphoblastic Leukemia
PETHEMA Foundation
Not applicable
330
A Coruña, Alava, Albacete, Alicante, Almería, Arrecife, Ávila, Badajoz
2026-03-06
Recruiting
Inhaled Sedation in Critically Ill Patients
NCT07000526Sedation, Airway Extubation
DrugsIsoflurane·Propofol
Instituto de Investigación Hospital Universitario La Paz
Phase 4
620
Orihuela, Arrecife, Galdakao, Albacete, Badalona, Barcelona, Jaén, Lleida
2025-12-15
Active, closed
Hoffmann-La Roche
Phase 2
193
Las Palmas de Gran Canaria, EL Palmar (EL Palmar), Albacete, Alicante, Barcelona, Madrid, Seville
2025-11-13
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Albacete, Logroño, Pozuelo de Alarcón, Torrejón de Ardoz, El Palmar
2025-11-11
Recruiting
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
NCT07785180Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Stemline Therapeutics, Inc.
Observational
140
Albacete, Alicante, Badalona, Burgos, Cáceres, Córdoba, Madrid, Oviedo
2025-10-17
Recruiting
Kura Oncology, Inc.
Phase 3
1,300
Seville, Zaragoza, Burgos, Salamanca, Albacete, Madrid, Oviedo, Valencia
2025-09-26
Recruiting
Pharmazz, Inc.
Phase 3
514
Badalona, Barcelona, Albacete, Madrid, El Palmar, Seville, Tarragona, A Coruña
2025-07-24
Recruiting
Corxel Pharmaceuticals
Phase 2/3
740
A Coruña, Albacete, Barcelona, Girona, Madrid, Málaga, Seville, Valencia
2025-05-15
Recruiting
Fundación EPIC
Observational
500
Albacete, Alicante, Badajoz, Castelló, Ciudad Real, Elche, L'Hospitalet de Llobregat, Laguna
2025-05-06
Recruiting
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 3
339
Albacete, Alicante, Barcelona, Valencia
2025-02-27
Active, closed
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
2,000
Albacete, Alicante, Barakaldo, Burgos, Cadiz, Cantabria, Córdoba, Donostia / San Sebastian
2025-02-12
Recruiting
Spanish Oncology Genito-Urinary Group
Observational
500
Albacete, Alicante, Almería, Córdoba, Granada, Jaén, Jerez de la Frontera, Málaga
2024-12-13
Recruiting
Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy
NCT06896266Arrhythmia, Cardiomyopathy, Arrhythmia-induced Cardiomyopathy (AiCM)
Hospital Universitario 12 de Octubre
Observational
109
Ciudad Real, Madrid, Albacete
2024-12-01
Active, closed
Daiichi Sankyo
Phase 3
700
Albacete, Alicante, Badalona, Barcelona, Burgos, Cáceres, Córdoba, Las Palmas
2024-11-19
Recruiting
Intra-Cellular Therapies, Inc.
Phase 2
320
Albacete, Badalona, Málaga, Zamora, Zaragoza
2024-10-22
Recruiting
Fundación para la Investigación del Hospital Clínico de Valencia
Phase 3
94
Alcorcón, Leganés, Albacete, Burgos, Córdoba, Valencia
2024-10-03
Recruiting
Intra-Cellular Therapies, Inc.
Phase 2
370
Albacete, Zamora, Zaragoza
2024-08-15
Active, closed
The Lymphoma Academic Research Organisation
Phase 3
790
Albacete, Barcelona, Las Palmas de Gran Canaria, Lleida, Madrid, Marbella, Oviedo, Salamanca
2024-06-07
Recruiting
Hyperangulated vs Macintosh Blades for Intubation With Videolaryngoscopy in ICU
NCT06322719Acute Respiratory Failure, Intubation, Intubation; Difficult or Failed, Videolaryngoscopy
Hospital Clinico Universitario de Santiago
Not applicable
1,036
Santiago de Compostela, A Coruña, Albacete, Barcelona, Cáceres, Denia, Elche, Gijón
2024-05-01
Recruiting
Reduction of the Incidence of NAV in Neonatal Units (INBERNAV-Neo)
NCT07240038Pneumonia Ventilator Associated, Pneumonia Neonatal, Healthcare-associated Infections
Biobizkaia Health Research Institute
Observational
1,500
A Coruña, Santiago de Compostela, Albacete, Badalona, Barcelona, Barakaldo, Bilbao, Burgos
2024-04-26
Active, closed
Fundación EPIC
Observational
501
Albacete, Alicante, Barakaldo, Boadilla del Monte, Ciudad Real, Granada, Huelva, L'Hospitalet de Llobregat
2024-02-26
Active, closed
Astellas Gene Therapies
Not applicable
119
Albacete, Barcelona, Donostia / San Sebastian, L'Hospitalet de Llobregat, Madrid, Valencia
2024-02-01
Recruiting
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
NCT07159750Migraine, Episodic Migraine, Chronic Migraine, Headache
Hospital Universitari Vall d'Hebron Research Institute
Observational
700
Badalona, Barcelona, L'Hospitalet de Llobregat, Mollet del Vallès, Viladecans, Albacete, Madrid, Zaragoza
2024-01-02
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Badalona, L'Hospitalet Del Llobregat, Barcelona, Santiago de Compostela, Madrid, Marbella, Albacete, Málaga
2023-12-31
Recruiting
DESTINY Breast Respond HER2-(Ultra)Low Europe
NCT05945732Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer, HER2-(Ultra)Low Expressing Breast Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
2,295
Albacete, Alicante, Alzira, Barakaldo, Barcelona, Bilbao, Cadiz, Cáceres
2023-10-24
Active, closed
AstraZeneca
Phase 3
5,511
A Coruña, Albacete, Alicante, Badalona, Barakaldo, Barcelona, Burgos, Castellon
2023-10-05
Recruiting
AstraZeneca
Phase 3
4,300
A Coruña, Albacete, Alcoy, Alicante, Alzira, Badajoz, Badalona, Barakaldo
2023-03-31
Active, closed
Janssen Research & Development, LLC
Phase 3
12,523
A Coruña, Albacete, Alicante, Badalona, Barakaldo, Barcelona, Córdoba, Girona
2023-02-15
Active, closed
Fundación EPIC
Not applicable
609
L'Hospitalet de Llobregat, A Coruña, Albacete, Alicante, Badalona, Barcelona, Cadiz, Castellon
2023-01-30
Recruiting
Greenwich LifeSciences, Inc.
Phase 3
2,250
Albacete, Alicante, Badajoz, Barcelona, Cáceres, Córdoba, El Palmar, Fuenlabrada
2022-12-16
Recruiting
The Impact of Radiotherapy on Oligometastatic Cancer
NCT05933876Metastasis, Metastatic Breast Cancer, Metastatic Prostate Cancer, Metastatic Colorectal Cancer
Institut Investigacio Sanitaria Pere Virgili
Observational
2,000
Albacete, Barcelona, Granada, Lleida, Madrid, Seville, Reus, Valencia
2022-12-01
Recruiting
PETHEMA Foundation
Phase 3
480
Alcalá de Henares, Pozuelo de Alarcón, Pamplona, Albacete, Badalona, Barcelona, Bilbao, Burgos
2022-11-10
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
Albacete, Barcelona, Cáceres, Las Palmas, Madrid, Oviedo, Salamanca, Santander
2022-02-28
Recruiting
National GMA Post-market Clinical Follow-up Study (GRACE)
NCT05636709Crohn Disease, Ulcerative Colitis
Adacyte Therapeutics SL
Observational
350
Albacete, Alicante, Badalona, Barcelona, Galdakao, Castellon, Cadiz, Córdoba
2022-01-11
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Santiago Compostela, Vitoria-Gasteiz, L'Hospitalet de Llobregat, Albacete, Barcelona, Logroño, Pozuelo de Alarcón, Torrejón de Ardoz
2021-12-13
Active, closed
Spanish Breast Cancer Research Group
Phase 3
27
A Coruña, Albacete, Alicante, Badajoz, Badalona, Barcelona, Bilbao, Cadiz
2021-09-14
Recruiting
Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen
NCT04891237Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
Drugs10,000 MG01·30,000 MG01
Inmunotek S.L.
Phase 3
180
Tarancón, Alcalá de Henares, Tres Cantos, Valdemoro, El Palmar, Albacete, Ávila, Badajoz
2021-06-14
Active, closed
ANGiographic Evaluation of Left Main Coronary Artery INtErvention
NCT04604197Coronary Occlusion, Left Main Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease
Fundación EPIC
Not applicable
400
Badalona, Barakaldo, Donostia / San Sebastian, Málaga, Galdakao, A Coruña, Albacete, Alicante
2021-04-16
Active, closed
Loxo Oncology, Inc.
Phase 3
238
L'Hospitalet de Llobregat, Toledo, Santiago de Compostela, Pozuelo de Alarcón, Madrid, Albacete, Barcelona, Cáceres
2021-03-09
Active, closed
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Observational
5,000
Albacete, Alcorcón, Alcoy, Alicante, Almería, Asturias, Badajoz, Barakaldo
2021-01-15
Active, closed
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
NCT04595565HER2-negative Breast Cancer, Triple Negative Breast Cancer
DrugsXeloda·Sacituzumab Govitecan·Paraplatin·Capecitabine
GBG Forschungs GmbH
Phase 3
1,332
Barakaldo, A Coruña, Albacete, Alcorcón, Alcoy, Alicante, Badalona, Barcelona
2020-10-28
Recruiting
Complejo Hospitalario Universitario de Albacete
Not applicable
273
Albacete
2020-01-01
Recruiting
PETHEMA Foundation
Not applicable
300
Badalona, A Coruña, Albacete, Alicante, Ávila, Barcelona, Bellvitge, Bilbao
2019-11-25
Active, closed
Concordance Between FFR and iFR for the Assessment of Intermediate Lesions in the Left Main Coronary Artery. A Prospective Validation of a Default Value for iFR
NCT03767621Coronary Artery Disease, Left Main Coronary Artery Stenosis, Left Main Coronary Artery Disease, Restenosis, Coronary
Fundación EPIC
Observational
300
Terrassa, Cartagena, El Palmar, Castellon, Galdakao, Albacete, Badajoz, Badalona
2019-02-19
Active, closed
PETHEMA Foundation
Phase 3
462
A Coruña, Albacete, Alicante, Badalona, Barcelona, Bilbao, Cáceres, Córdoba
2018-10-22
Recruiting
Spanish Breast Cancer Research Group
Observational
8,000
Pamplona, Avilés, San Cristóbal de La Laguna, A Coruña, Albacete, Alicante, Badajoz, Badalona
2018-01-18
Recruiting
Thoracic Tumours Register
NCT02941458Thoracic Tumors
Spanish Lung Cancer Group
Observational
10,000
Ferrol, Albacete, Alcoy, Alicante, Elche, Elda, Badalona, Barcelona
2016-07-21
Active, closed
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
NCT01272037Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma
DrugsTamoxifen Citrate·Tamoxifen·Exemestane·Anastrozole
National Cancer Institute (NCI)
Phase 3
5,018
A Coruña, Albacete, Barcelona, Castellon, Cáceres, Donostia / San Sebastian, Girona, Madrid
2011-02-28
Recruiting
Manuel Monreal
Observational
120,000
A Coruña, Cee, Ferrol, Ribeira, Santiago de Compostela, Albacete, Alicante, Elche
2001-03
Rows per page Showing 1–54 of 54
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/albacete

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 54 of those studies with a site in Albacete.

How many clinical trials are recruiting in Albacete?

32 of the 54 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 2 have not yet opened recruitment, 20 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Albacete), 54 studies
PhaseStudiesRecruitingShare
Phase 321938.9%
Observational171231.5%
Not applicable7313%
Phase 2549.3%
Phase 4223.7%
Phase 1/2111.9%
Phase 2/3111.9%

Most active sponsors

Lead sponsors with the most studies (Albacete)
Lead sponsorStudiesRecruiting
Fundación EPIC51
PETHEMA Foundation53
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company31
AstraZeneca21
Biobizkaia Health Research Institute22
Intra-Cellular Therapies, Inc.22
Novartis Pharmaceuticals21
Spanish Breast Cancer Research Group21
AB Science10
Adacyte Therapeutics SL11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.